Dr Adeeba Kamarulzaman says Malaysia’s position as an upper-middle-income nation means that the country doesn’t automatically qualify for generic price negotiations.
The only three Asean countries excluded by Gilead Sciences for generic versions of remdesivir in its new licencing agreements are Malaysia, Singapore, and Brunei.